Get the latest insights from Moderna's Q3 2025 earnings call: revenue guidance updates, cost reduction highlights, and pipeline progress.

Doctors in Belgium met with a real head-scratcher when an 83-year-old married man came in with a rare form of secondary ...

The controlled multi-centre, randomised, prospective trial is investigating the therapy in kidney transplant recipients.

Kamada (KMDA) announced that the first patient was enrolled into an investigator-initiated post-marketing clinical trial of CYTOGAM, CMV-IGIV, to ...

The latest announcement is out from Kamada ( (IL:KMDA) ).

The study, titled “ Strategic Help with Immunoglobulin to Enhance protection against Late Disease (CMV) ” or SHIELD, is a prospective, randomized, controlled multicenter investigator-initiated study ...

A comprehensive eight-year study examining audiological outcomes of newborns screened for congenital cytomegalovirus (cCMV) ...

People who caught the flu were up to six times more likely to have a heart attack in the month after the infection.

Topline results were announced from a phase 3 study evaluating Moderna’s cytomegalovirus vaccine candidate, mRNA-1647.

CMV is particularly linked to immune remodeling, including the expansion of highly differentiated CD8⁺ T cells (Tem, Temra), ...

CAMBRIDGE, MA / ACCESS Newswire / October 22, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced topline results from a Phase 3 pivotal trial evaluating the efficacy of mRNA-1647, the Company’s ...

While development has been scrapped in CMV, a Phase II trial investigating the candidate in bone marrow transplant patients will continue.